Spark Therapeutics' $4.8B deal confirmed as biggest-ever VC-backed exit in Philly - Technical.ly Philly

Business

Mar. 1, 2019 1:21 pm

Spark Therapeutics’ $4.8B deal confirmed as biggest-ever VC-backed exit in Philly

Quick update on this week's news: The University City life sciences company's acquisition by Swiss pharma giant Roche is the biggest acquisition ever of a VC-backed company within city limits, per PitchBook and PACT.
Founded in 2013, the UCity company announced its acquisition this week.

Founded in 2013, the UCity company announced its acquisition this week.

(Courtesy photo)

The eye-popping $4.8 billion sticker price on Spark Therapeutics’ acquisition deal with Roche announced on Monday is shaping up to be the largest exit ever within city limits for a venture-backed company, according to data from financial data provider PitchBook and the Philadelphia Alliance for Capital and Technologies (PACT).

“Filtering down to just Philadelphia proper does reveal that Spark Therapeutics, once the deal closes, will be the biggest exit ever for Philly-based venture-backed exits,” the company said in an email, citing data from an upcoming report.

According to the Seattle-based company’s data, the current holder of the largest Philly-proper exit title goes to Avid Radiopharmaceuticals, which in 2010 announced its acquisition by Lilly in a deal valued at up to $800 million.

Founded in 2013, Spark is a publicly traded spinout of Children’s Hospital of Philadelphia (CHOP), which invested $33 million in the company. The Philadelphia Inquirer reports that CHOP stands to reap a total return of $430 million for its minority stake in Spark Therapeutics.

As part of the acquisition deal, the company will remain based out of 3711 Market St., and continue to do business as a standalone Roche company.

“This transaction demonstrates the enormous value that global biotech companies like Roche see in gene therapy, a field in which Philadelphia is the unquestioned leader,” said Saul Behar, senior VP of  advancement and strategic initiatives at the University City Science Center, the West Philly research park where Spark began and grew its operations. “[This] further validates Greater Philadelphia’s status as a biotech hub with a very bright future.”

Spark CEO Jeff Marrazzo said the deep pool of resources from Roche, the company plans to “accelerate the development of more gene therapies for more patients for more diseases and further expedite our vision of a world where no life is limited by genetic disease.”

Advertisement

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Success in life sciences begets more success: What Philly leaders say about the industry’s growth

Philadelphia is having its best year for VC deals since 2000

These startups won big money at PACT’s live, ‘Shark Tank’-like pitch event

SPONSORED

Philly

How Relay is helping enterprise clients get proactive about customer engagement

Philadelphia OR Baltimore

Technically Media

Technical.ly Editorial Intern (Spring 2019)

Apply Now

Horsham

Penn Mutual Life Insurance Co

Product Systems Specialist

Apply Now

Chesterbrook, PA

Deacom

Senior Software Developer

Apply Now

Exton cell and gene therapy company Fibrocell will be acquired for $63.3M

You can make a literal elevator pitch to Robin Hood Ventures investors

What’s slowing a wider adoption of impact investing?

SPONSORED

Philly

These hiring companies want to meet you at NET/WORK Suburbs

Philadelphia, PA

PromptWorks

Senior React Native Engineer

Apply Now

Philadelphia, PA

PromptWorks

Software Engineer

Apply Now

Philadelphia, PA

Vistar Media

QA Engineer

Apply Now

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!